Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jon D Morrow

Showing results (11-20 of 16) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 16 results.
BJU International|September 24, 2010
Patient-optimized doses of fesoterodine improve bladder symptoms in an open-label, flexible-dose studyJean-Jacques Wyndaele, Evan R Goldfischer, Jon D Morrow, et al.
BMJ Evidence-Based Medicine|July 2, 2025
Understanding synthetic data: artificial datasets for real-world evidenceRandi Foraker, Jon D Morrow, Julie A Johnson, et al.
Current Medical Research and Opinion|July 16, 2009
Effects of tolterodine ER on patient-reported outcomes in sexually active women with overactive bladder and urgency urinary incontinenceRebecca G Rogers, Gloria Bachmann, Harriette Scarpero, et al.
Journal of the American Medical Informatics Association : JAMIA|March 31, 2022
Demonstrating an approach for evaluating synthetic geospatial and temporal epidemiologic data utility: results from analyzing >1.8 million SARS-CoV-2 tests in the United States National COVID Cohort Collaborative (N3C)Jason A Thomas, Randi E Foraker, Noa Zamstein, et al.
Urology|November 26, 2009
Randomized, double-blind, placebo-controlled trial of flexible-dose fesoterodine in subjects with overactive bladderRoger R Dmochowski, Kenneth M Peters, Jon D Morrow, et al.
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research|April 12, 2025
Research Method, Conduct, and Reporting Considerations for Improving the Quality of Non-Hypothesis-Evaluating Treatment Effectiveness Analyses Using Real-World Data: An ISPOR Special Interest Group ReportEric Barrette, William H Crown, Melinda Hanisch, et al.
Pageof 2

Showing results (11-20 of 16) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 16 results.
BJU International|September 24, 2010
Patient-optimized doses of fesoterodine improve bladder symptoms in an open-label, flexible-dose studyJean-Jacques Wyndaele, Evan R Goldfischer, Jon D Morrow, et al.
BMJ Evidence-Based Medicine|July 2, 2025
Understanding synthetic data: artificial datasets for real-world evidenceRandi Foraker, Jon D Morrow, Julie A Johnson, et al.
Current Medical Research and Opinion|July 16, 2009
Effects of tolterodine ER on patient-reported outcomes in sexually active women with overactive bladder and urgency urinary incontinenceRebecca G Rogers, Gloria Bachmann, Harriette Scarpero, et al.
Journal of the American Medical Informatics Association : JAMIA|March 31, 2022
Demonstrating an approach for evaluating synthetic geospatial and temporal epidemiologic data utility: results from analyzing >1.8 million SARS-CoV-2 tests in the United States National COVID Cohort Collaborative (N3C)Jason A Thomas, Randi E Foraker, Noa Zamstein, et al.
Urology|November 26, 2009
Randomized, double-blind, placebo-controlled trial of flexible-dose fesoterodine in subjects with overactive bladderRoger R Dmochowski, Kenneth M Peters, Jon D Morrow, et al.
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research|April 12, 2025
Research Method, Conduct, and Reporting Considerations for Improving the Quality of Non-Hypothesis-Evaluating Treatment Effectiveness Analyses Using Real-World Data: An ISPOR Special Interest Group ReportEric Barrette, William H Crown, Melinda Hanisch, et al.
Pageof 2